Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomidesensitive cytogenetic abnormality

Blood

Volumn 113, Issue 5, 2009, Pages 1200-1201

  Mesa, Ruben A ^a   Hanson, Curtis A ^a   Ketterling, Rhett P ^a   Schwager, Susan ^a   Knudson, Ryan A ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; LENALIDOMIDE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; THALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CORRELATION ANALYSIS; FOLLOW UP; HISTOLOGY; HUMAN; KARYOTYPE; LETTER; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; PATHOGENESIS; PATHOLOGY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REMISSION; TREATMENT RESPONSE; TRISOMY 13; CHROMOSOME 13; FEMALE; GENETICS; MALE; MYELOID METAPLASIA; RETROSPECTIVE STUDY; TRISOMY;

ANTINEOPLASTIC AGENTS; CHROMOSOMES, HUMAN, PAIR 13; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES; PRIMARY MYELOFIBROSIS; RETROSPECTIVE STUDIES; THALIDOMIDE; TRISOMY;

EID: 60849118093     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-10-182170     Document Type: Letter

References (4)

1. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549-557.
2. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108:1158-1164.
3. Mesa RA, Tefferi A, Li CY, Steensma DP. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome. Leukemia. 2006;20:2063-2064.
4. Fehniger TA, Byrd JC, Marcucci G, et al. Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood. 2009;113:1002-1005.